Biogen Idec Inc. BIIB, Human Genome Sciences Finds Cure Against Lupus
Biogen Idec Inc.
Rochester, NY 8/31/2009 09:17 AM GMT (TransWorldNews)
Lupus is a chronic autoimmune disease, in which the body’s immune system attacks its own cells and tissues, damaging the organs. The disease affects various body parts, including joints, skin, blood and kidneys. Patients may suffer from moderate and sever Lupus.
Developing a drug for lupus continues to be a formidable challenge. Lupus drug space has attracted the interest of investors after Human Genome Sciences Inc. reported positive late-stage trial data for its experimental lupus therapy, Benlysta, defying the skeptics last month. Immunomedics Inc. is also developing a drug for lupus, has some good news to offer on the lupus front. In a new phase IIb clinical study, the company's experimental drug Epratuzumab demonstrated clinical meaningful treatment effect over placebo in lupus patients.
WallStreetsHottestStocks.com is a free award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks daily to find those that meet our criteria and when we find one, we send you an alert.
Scroll To the bottom of this page for FREE stock alerts, or visit our site now.
Disclaimer: Full disclaimer at http://WallStreetsHottestStocks.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither WallStreetsHottestStocks.com, nor any of its affiliates are registered investment advisors or broker dealers.
info@wallstreetshotteststocks.com
WallStreetsHottestStocks.com
